Log in

NASDAQ:IDXGInterpace Diagnostics Group Stock Price, Forecast & News

+1.73 (+39.23 %)
(As of 07/3/2020 04:00 PM ET)
Today's Range
Now: $6.14
50-Day Range
MA: $5.14
52-Week Range
Now: $6.14
Volume5.35 million shs
Average Volume431,863 shs
Market Capitalization$24.81 million
P/E RatioN/A
Dividend YieldN/A
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Read More
Interpace Diagnostics Group logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
Current SymbolNASDAQ:IDXG



Sales & Book Value

Annual Sales$24.08 million
Book Value$3.41 per share


Net Income$-26,730,000.00
Net Margins-110.80%


Market Cap$24.81 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.

Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

How has Interpace Diagnostics Group's stock been impacted by COVID-19 (Coronavirus)?

Interpace Diagnostics Group's stock was trading at $6.46 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IDXG stock has decreased by 5.0% and is now trading at $6.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Interpace Diagnostics Group?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Interpace Diagnostics Group.

When is Interpace Diagnostics Group's next earnings date?

Interpace Diagnostics Group is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Interpace Diagnostics Group.

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) issued its earnings results on Thursday, June, 25th. The business services provider reported ($2.32) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.24) by $1.08. The business services provider had revenue of $9.20 million for the quarter, compared to the consensus estimate of $8.95 million. Interpace Diagnostics Group had a negative return on equity of 119.88% and a negative net margin of 110.80%. View Interpace Diagnostics Group's earnings history.

What guidance has Interpace Diagnostics Group issued on next quarter's earnings?

Interpace Diagnostics Group updated its second quarter 2020 After-Hours earnings guidance on Thursday, June, 25th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $5.6-6 million, compared to the consensus revenue estimate of $6.27 million.

What price target have analysts set for IDXG?

5 brokerages have issued 1 year price targets for Interpace Diagnostics Group's shares. Their forecasts range from $3.00 to $12.00. On average, they expect Interpace Diagnostics Group's stock price to reach $8.81 in the next year. This suggests a possible upside of 43.5% from the stock's current price. View analysts' price targets for Interpace Diagnostics Group.

Has Interpace Diagnostics Group been receiving favorable news coverage?

Media coverage about IDXG stock has trended negative on Sunday, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a daily sentiment score of -2.4 on InfoTrie's scale. They also gave news articles about the business services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about Interpace Diagnostics Group.

Are investors shorting Interpace Diagnostics Group?

Interpace Diagnostics Group saw a decline in short interest in June. As of June 15th, there was short interest totaling 99,100 shares, a decline of 18.6% from the May 31st total of 121,700 shares. Based on an average trading volume of 80,900 shares, the short-interest ratio is currently 1.2 days. Approximately 2.5% of the company's stock are short sold. View Interpace Diagnostics Group's Current Options Chain.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), AT&T (T), Trevena (TRVN), Genocea Biosciences (GNCA) and AbbVie (ABBV).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the following people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 67, Pay $621.68k)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 53, Pay $424.24k)
  • Mr. Fred S. Knechtel, CFO, Treasurer & Company Sec. (Age 59)
  • Mr. Glenn Gershon, Sr. VP of Operations
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 52)

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $6.14.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $24.81 million and generates $24.08 million in revenue each year. The business services provider earns $-26,730,000.00 in net income (profit) each year or ($5.58) on an earnings per share basis. Interpace Diagnostics Group employs 176 workers across the globe.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is www.interpace.com.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.